Table 2.

Discriminatory capability of biomarkers

		Affected area					MFI
Biomarker candidate	Control vs. cohort	AUC	95% Confidence interval			Sensit. at 90% specif.	AUC	95% Confidence interval			Sensit. at 90% specif.
CD4	RA	0.64	0.44	-	0.84	7.35	0.57	0.35	-	0.78	9.79
	RA(+)	0.04	0.04	-	0.04	4.27	0.10	0.08	-	0.11	9.60
	RA(++)	0.68	0.43	-	0.94	19.51	0.63	0.35	-	0.90	12.75
CD11b	RA	0.79	0.63	-	0.95	51.82	0.76	0.60	-	0.93	51.76
	RA(+)	0.41	0.14	-	0.68	40.81	0.46	0.10	-	0.82	45.86
	RA(++)	0.95	0.85	-	1.00	85.09	0.88	0.68	-	1.00	71.47
CD29	RA	0.83	0.69	-	0.98	51.53	0.69	0.50	-	0.88	50.22
	RA(+)	0.59	0.12	-	1.00	58.59	0.62	0.00	-	1.00	61.82
	RA(++)	0.82	0.63	-	1.00	38.81	0.49	0.13	-	0.84	26.72
CD38	RA	0.72	0.54	-	0.91	22.23	0.70	0.50	-	0.89	17.68
	RA(+)	0.11	0.10	-	0.11	10.59	0.20	0.16	-	0.23	19.64
	RA(++)	0.86	0.61	-	1.00	69.11	0.70	0.47	-	0.93	5.37
CD64	RA	0.89	0.78	-	1.00	76.31	0.82	0.66	-	0.97	69.72
	RA(+)	0.66	0.00	-	1.00	65.72	0.63	0.00	-	1.00	63.09
	RA(++)	1.00	1.00	-	1.00	100.00	0.95	0.78	-	1.00	88.39
CD90	RA	0.83	0.69	-	0.97	57.97	0.78	0.62	-	0.94	53.55
	RA(+)	0.70	0.00	-	1.00	69.70	0.63	0.00	-	1.00	63.21
	RA(++)	0.78	0.59	-	0.98	10.12	0.72	0.50	-	0.94	6.58
CD271	RA	0.46	0.26	-	0.66	7.43	0.47	0.27	-	0.67	9.97
	RA(+)	0.03	0.03	-	0.03	3.31	0.03	0.03	-	0.03	3.28
	RA(++)	0.58	0.27	-	0.88	15.48	0.70	0.44	-	0.95	18.79
CD304	RA	0.72	0.54	-	0.89	42.98	0.69	0.50	-	0.87	42.23
	RA(+)	0.41	0.10	-	0.73	41.31	0.33	0.12	-	0.55	33.35
	RA(++)	0.82	0.62	-	1.00	45.95	0.94	0.83	-	1.00	84.92
HLA-DR	RA	0.87	0.74	-	0.99	65.01	0.86	0.74	-	0.99	69.28
	RA(+)	0.72	0.00	-	1.00	72.09	0.77	0.00	-	1.00	76.79
	RA(++)	0.82	0.59	-	1.00	53.56	0.77	0.49	-	1.00	55.01

Expression of listed surface antigens was analyzed on synovial tissue with LSC. Data were obtained with ROC analysis. Bold, AUC > 0.85.